Dr. Alberto Ascherio of Harvard and Dr. Stephen Hauser of the University of California, San Francisco (UCSF) — will share $3 ...

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis (MS) and the other detailing the ...

Although EBV is treatable, it can trigger an array of diseases including autoimmune diseases. One major risk factor of multiple sclerosis (MS) includes EBV infection. MS is a chronic inflammatory ...

TG Therapeutics (TGTX) announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis ...

Zenas BioPharma, Inc.’s ZBIO share price has surged by 11.36%, which has investors questioning if this is right time to sell.

In this week’s edition of InnovationRx, we look at the impact of tariffs on healthcare costs, pioneers of treating MS, AI for ...

This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

Researchers who discovered a mechanism that prevents B cells from attacking the body’s own tissues in autoimmune diseases win ...

In a recent case report published in Frontiers in Immunology, scientists in Canada described how an experimental treatment using a naturally derived substance called ibogaine appeared to improve ...